Evidence map›Paper›PMID 39902067›Full record

ArticleInternational journal of nanomedicine2025

Human Primary Monocytes as a Model for in vitro Immunotoxicity Testing: Evaluation of the Regulatory Properties of TiO

Tereza Svadlakova, Martina Kolackova, Pavel Kulich, Jan Kotoucek, Michaela Rosecka, Jan Krejsek, Zdeněk Fiala, Ctirad Andrýs

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tereza SvadlakovaDepartment of Clinical Immunology and Allergology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.ORCID 0000-0002-1581-5531
Martina KolackovaDepartment of Clinical Immunology and Allergology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
Pavel KulichDepartment of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czech Republic.
Jan KotoucekDepartment of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czech Republic.
Michaela RoseckaDepartment of Clinical Immunology and Allergology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.ORCID 0000-0003-2595-9990
Jan KrejsekDepartment of Clinical Immunology and Allergology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
Zdeněk FialaDepartment of Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
Ctirad AndrýsDepartment of Clinical Immunology and Allergology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A critical step preceding the potential biomedical application of nanoparticles is the evaluation of their immunomodulatory effects. Such nanoparticles are expected to enter the bloodstream where they can be recognized and processed by circulating monocytes. Despite the required biocompatibility, this interaction can affect intracellular homeostasis and modulate physiological functions, particularly inflammation. This study focuses on titanium dioxide (TiO Methods: Monocyte viability, phenotypic changes, and cytokine production were determined after exposure to TiO Results: The selected TiO Conclusion: This study confirmed a non-negligible modulatory effect on primary monocytes in their inflammasome-based response and differentiation ability.

Indexed as

Metal NanoparticlesMonocytesNanoparticlesTitaniumAcetylmuramyl-Alanyl-IsoglutamineCell DifferentiationCells, CulturedCell SurvivalCytokinesHumansInflammasomesInterleukin-10Interleukin-1betaLipopolysaccharidesMacrophagesNLR Family, Pyrin Domain-Containing 3 ProteinAcetylmuramyl-Alanyl-IsoglutamineCytokinesInflammasomesInterleukin-10Interleukin-1betaLipopolysaccharidesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanTitaniumtitanium dioxideimmunomodulationmacrophagesmonocytesNLRP3polarizationTiO2 nanoparticles

Identifiers

PMID39902067
PMCPMC11789775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.